NL9201440A - Triantennaire clusterglycosiden, hun bereiding en toepassing. - Google Patents

Triantennaire clusterglycosiden, hun bereiding en toepassing. Download PDF

Info

Publication number
NL9201440A
NL9201440A NL9201440A NL9201440A NL9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A
Authority
NL
Netherlands
Prior art keywords
group
glycoside
formula
residue
compound
Prior art date
Application number
NL9201440A
Other languages
English (en)
Dutch (nl)
Original Assignee
Univ Leiden
Nl Hartstichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Nl Hartstichting filed Critical Univ Leiden
Priority to NL9201440A priority Critical patent/NL9201440A/nl
Priority to JP6506123A priority patent/JPH08502726A/ja
Priority to US08/382,022 priority patent/US5885968A/en
Priority to AU48355/93A priority patent/AU674160B2/en
Priority to ES93921124T priority patent/ES2122041T3/es
Priority to DE69319912T priority patent/DE69319912T2/de
Priority to DK93921124T priority patent/DK0655070T3/da
Priority to AT93921124T priority patent/ATE168694T1/de
Priority to PCT/NL1993/000169 priority patent/WO1994004545A1/fr
Priority to EP93921124A priority patent/EP0655070B1/fr
Publication of NL9201440A publication Critical patent/NL9201440A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NL9201440A 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing. NL9201440A (nl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.
JP6506123A JPH08502726A (ja) 1992-08-11 1993-08-11 ３分枝性クラスタグリコシドの調製およびその用途
US08/382,022 US5885968A (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
AU48355/93A AU674160B2 (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
ES93921124T ES2122041T3 (es) 1992-08-11 1993-08-11 Glicosidos triantenarios aglomerados, su preparacion y utilizacion.
DE69319912T DE69319912T2 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung
DK93921124T DK0655070T3 (da) 1992-08-11 1993-08-11 Triantennære klusterglycosider, deres fremstilling og anvendelse
AT93921124T ATE168694T1 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung
PCT/NL1993/000169 WO1994004545A1 (fr) 1992-08-11 1993-08-11 Glycosides en agglomerat triantennaires, leur preparation et utilisation
EP93921124A EP0655070B1 (fr) 1992-08-11 1993-08-11 Glycosides en agglomerat triantennaires, leur preparation et utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.
NL9201440 1992-08-11

Publications (1)

Publication Number Publication Date
NL9201440A true NL9201440A (nl) 1994-03-01

Family

ID=19861173

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.

Country Status (10)

Country Link
US (1) US5885968A (fr)
EP (1) EP0655070B1 (fr)
JP (1) JPH08502726A (fr)
AT (1) ATE168694T1 (fr)
AU (1) AU674160B2 (fr)
DE (1) DE69319912T2 (fr)
DK (1) DK0655070T3 (fr)
ES (1) ES2122041T3 (fr)
NL (1) NL9201440A (fr)
WO (1) WO1994004545A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5122796A (en) * 1995-03-31 1996-10-16 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
PT2539451E (pt) 2010-02-24 2016-03-28 Arrowhead Res Corp Composições para entrega de arnsi dirigida ao alvo
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP3192800A1 (fr) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Fraction de ciblage complexe de galactose-modulateur pharmacocinétique pour arnsi
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
MX2014001971A (es) 2011-08-26 2014-03-31 Arrowhead Res Corp Polimeros de poli(vinilester) para suministro de acido nucleico in vivo.
US20140100178A1 (en) * 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
KR20150083920A (ko) 2012-11-15 2015-07-20 로슈 이노베이션 센터 코펜하겐 에이/에스 항 apob 안티센스 접합체 화합물
KR20150110562A (ko) 2013-01-30 2015-10-02 에프. 호프만-라 로슈 아게 Ｌｎａ 올리고뉴클레오타이드 탄수화물 컨쥬게이트
WO2014118272A1 (fr) 2013-01-30 2014-08-07 Santaris Pharma A/S Conjugués glucidiques d'oligonucléotides antimir-22
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US9803205B2 (en) 2015-03-17 2017-10-31 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of factor XII
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
JP6748219B2 (ja) 2016-03-14 2020-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｄ−ｌ１発現低減用のオリゴヌクレオチド
EP3228326A1 (fr) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Acide nucléique lié à un glycoconjugué trivalent
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
AU2018208505B2 (en) 2017-01-10 2024-03-07 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
WO2018185240A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Produits et compositions
WO2018185252A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Conjugués d'acides nucléiques
WO2018185241A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Produits et compositions
EP3550022A1 (fr) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produits et compositions
WO2018185253A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Acides nucléiques bicaténaires modifiés par un ligand
EP3483269A1 (fr) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
EP3385381A1 (fr) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produits et compositions
WO2018185239A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Produits et compositions
EP3385380A1 (fr) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produits et compositions
EP3385272A1 (fr) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Nouveaux conjugués de ligand d'oligonucléotide
TN2020000039A1 (en) 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
SG11201912188RA (en) 2017-09-14 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
TWI762732B (zh) 2017-10-16 2022-05-01 瑞士商赫孚孟拉羅股份公司 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
AU2018352379A1 (en) 2017-10-17 2020-06-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
EP3710586B1 (fr) 2017-11-13 2022-11-23 Silence Therapeutics GmbH Produits et compositions
EP3483270A1 (fr) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
MA51707A (fr) 2017-11-13 2020-09-23 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression d'un gène cible comprenant des liaisons phosphorodithioate
CA3118327A1 (fr) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule
KR20200140322A (ko) 2018-04-05 2020-12-15 사일런스 테라퓨틱스 게엠베하 안티센스 가닥의 5' 단부에 비닐포스포네이트를 갖는 siRNA
EP3550021A1 (fr) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produits et compositions pour l'inhibition d'expression d'un gène cible
PE20210346A1 (es) 2018-07-03 2021-02-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
EP3598995A1 (fr) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Produits et compositions
EP3844274A1 (fr) 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Manipulation de néoantigène à l'aide de composés de modulation d'épissage
BR112021009213A2 (pt) 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula
EP3884052A1 (fr) 2018-11-23 2021-09-29 Silence Therapeutics GmbH Acides nucléiques permettant d'inhiber l'expression de c3 dans une cellule
EP3730617A1 (fr) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Acides nucléiques pour inhiber l'expression de c3 dans une cellule
KR20210130736A (ko) 2019-02-07 2021-11-01 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스 감염에 대한 RNAi 작용제
JP7503072B2 (ja) 2019-02-26 2024-06-19 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドの製剤化方法
WO2020225301A1 (fr) 2019-05-07 2020-11-12 Universität Bern Acides nucléiques pour inhiber l'expression de pros1 dans une cellule
US20220305046A1 (en) 2019-06-06 2022-09-29 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
EP3986562A1 (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'arni ciblant le virus de l'hépatite b
BR112022003513A2 (pt) 2019-08-27 2022-05-17 Silence Therapeutics Gmbh Ácidos nucleicos para inibição da expressão de c3 em uma célula
EP4081639A1 (fr) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Association pharmaceutique d'un oligonucléotide thérapeutique ciblant le vhb et un agoniste de tlr7 pour le traitement du vhb
AU2020415322A1 (en) 2019-12-24 2022-06-16 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
JP2023519246A (ja) 2020-03-26 2023-05-10 アローヘッド ファーマシューティカルズ インコーポレイテッド ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法
CA3184050A1 (fr) 2020-05-27 2021-12-02 ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE Acides nucleiques pour inhiber l'expression de cnnm4 dans une cellule
US20230348905A1 (en) 2020-09-15 2023-11-02 Arrowhead Pharmaceuticals, Inc. Methods for the reduction of z-aat protein levels
WO2022096424A1 (fr) 2020-11-04 2022-05-12 Universität Bern Acides nucléiques pour inhiber l'expression de pros1 dans une cellule
WO2022184852A1 (fr) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Acides nucléiques conjugués comprenant un phosphorodithioate pour inhiber l'expression génique dans une cellule
WO2022223557A1 (fr) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression de xdh dans une cellule
CN117651771A (zh) 2021-04-27 2024-03-05 赛伦斯治疗有限责任公司 用于治疗骨髓增殖性病症的靶向TMPRSS6的siRNA
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
EP4396346A1 (fr) 2021-09-02 2024-07-10 Silence Therapeutics GmbH Acides nucléiques pour inhiber l'expression du facteur b du complément (cfb) dans une cellule
WO2023233290A1 (fr) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Agents d'arni ciblant pd-l1
WO2024126687A1 (fr) 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Acides nucléiques conjugués à une fraction de liaison à l'albumine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US751219A (en) * 1904-02-02 Leaf-turner
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
FR2637185A1 (fr) * 1988-10-05 1990-04-06 Ire Celltarg Sa Vecteurs synthetiques de faible poids moleculaire, utilisation en therapie ciblee et en imagerie medicale et procedes de preparation
ATE190619T1 (de) * 1993-09-01 2000-04-15 Akzo Nobel Nv Biskonjugate, die zwei saccharide und einen spacer enthalten

Also Published As

Publication number Publication date
ATE168694T1 (de) 1998-08-15
WO1994004545A1 (fr) 1994-03-03
DE69319912D1 (de) 1998-08-27
AU674160B2 (en) 1996-12-12
JPH08502726A (ja) 1996-03-26
AU4835593A (en) 1994-03-15
DE69319912T2 (de) 1999-04-15
ES2122041T3 (es) 1998-12-16
DK0655070T3 (da) 1999-04-26
EP0655070B1 (fr) 1998-07-22
US5885968A (en) 1999-03-23
EP0655070A1 (fr) 1995-05-31

Similar Documents

Publication Publication Date Title
NL9201440A (nl) Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU681010B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
EP0811011B1 (fr) Composes bioactifs conjugues a des hydrates de carbone
US5354853A (en) Phospholipid-saccharide conjugates
HUT74506A (en) Sialyl lewis-x analogues as inhibitors of cellular adhesion
JPH10507742A (ja) シアル酸／フコースベースの医薬
US20050187171A1 (en) Glycomimetic antagonists for both E-and P-selectins
CA2160100A1 (fr) Conjugues de carbohydrate, inhibiteurs de l'adherence cellulaire
EP1763533B1 (fr) Antagoniste specifique pour e-selectines et p-selectines
AU678373B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
JP2535048B2 (ja) 新規ジサッカライド誘導体及びその塩
EP1549658B1 (fr) Composes a base de glucose presentant une affinite pour la selectine-p
JP2774429B2 (ja) 糖骨格を有する分枝鎖型誘導体
WO1999010359A2 (fr) Composes organiques
JP2951975B2 (ja) 抗腫瘍剤
JPH06199884A (ja) 新規糖脂質誘導体
WO1998055149A1 (fr) Utilisation de vecteurs medicamenteux pour produire des medicaments migrants dans les ganglions lymphatiques
WO1991008748A1 (fr) Synthese de saccharides recepteurs de rotavirus
IKAMI et al. Synthetic studies on sialoglycoconjugares. Part CVII. Synthetic Studies on Selectin Ligands/Inhibitors. Synthesis and Biological Evaluation of Sulfated and Phosphorylated. BETA.-D-Galacto-and Lactopyranosides Containing Fatty-Alkyl Residues of Different Carbon Chain Lengths.
JPH10152498A (ja) 糖脂質誘導体、それを有効成分とする免疫抑制剤およびその製造用中間体
Wright Synthesis of glycoconjugates affecting cell adhesion

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed